HD-OPM Archive

Supplements for the heart: what has evidence and what doesn't

A summary of which supplements have randomized-trial support for heart outcomes (omega-3, CoQ10 in heart failure, folic acid for stroke, cocoa flavanols), which have only risk-factor or early data, and which are unproven or possibly harmful.

15 min read58 group posts cited52 studies discussed3 chartsEvidence through Nov 2026AI Summary of posts by Louis Nervegna and Gokhan Can
Key takeaways
  • A pooled review of 884 randomized trials of 27 micronutrients (883,627 participants) found lower heart-attack risk with omega-3 (RR 0.85), lower stroke with folic acid (RR 0.84) and lower all-cause mortality with CoQ10 (RR 0.68), but no effect of vitamins C, D, E or selenium on cardiovascular disease, and higher mortality with beta-carotene (RR 1.10).
  • In 40 omega-3 trials (135,267 people), heart attacks fell 13% and fatal heart attacks 35%; the authors suggest 1,000-2,000 mg/day of EPA plus DHA, and the post warns of a small rise in atrial fibrillation at high doses.
  • In the 420-patient Q-SYMBIO trial, CoQ10 (100 mg three times a day for 2 years) added to standard care lowered cardiovascular death from 16% to 9% in heart failure.
  • Supplements for plaque (gotu kola, aged garlic, nattokinase, vitamin K2) rest on small studies or single cases; the 2026 JAMA Cardiology trial found K2 slowed calcium progression but not plaque volume, and its effect on heart attacks is unknown.
  • Some supplements have signals of harm: L-arginine after a heart attack (6 deaths vs 0 in a stopped trial), L-carnitine (more carotid plaque stenosis in 6 months), and very high vitamin D (hypercalcemia).
  • The group's admins suggest weighing unproven supplements as probabilities, not certainties, never replacing proven treatments, and checking with a doctor before combining them with medicines such as blood thinners.
In this summary
  1. What the large reviews show
  2. Supplements with the best support
  3. Mixed or early evidence
  4. Supplements for plaque: promising but unproven
  5. Possible harms and hype
  6. What this means for you
  7. Frequently asked questions
  8. The evidence behind this summary

Which supplements have meaningful evidence for heart health, and which are hype? From the group's posts, the honest answer is that only a few have randomized-trial evidence on heart outcomes. Omega-3 fats have the broadest support, CoQ10 has support in heart failure specifically, and folic acid has support for stroke. Most of the rest have effects on blood pressure, lipids or glucose, early signals in small studies, or animal data only. A few appear to carry real risks.

The two admins, Louis Nervegna and Gokhan Can, take supplements themselves and say so. Gokhan notes that he takes multiple supplements, each with limited evidence, and that the aim is to stay grounded about what to expect.1 Louis stresses that an unstudied intervention is "indeterminate", not proven useless, and that it is unwise to bet your life on indeterminate items; each person has to assign their own subjective probability.2 Nothing here is individual medical advice, and the admins recommend discussing supplements with your doctor.

A note on terms. An RCT is a randomized controlled trial, the strongest design for testing a treatment. A hard endpoint is an event such as a heart attack, stroke or death, as opposed to a risk factor or surrogate such as cholesterol, blood pressure or a calcium score. Many supplements improve surrogates without proof that events fall.

884randomized trials of 27 micronutrients pooled in one review; only a few lowered heart attacks, strokes or deaths3
13%fewer heart attacks with omega-3 (EPA plus DHA) across 40 trials and 135,267 people4
16% → 9%cardiovascular death with CoQ10 added to standard heart failure care in Q-SYMBIO5
6 vs 0deaths on L-arginine versus placebo after a heart attack, and the trial was stopped6

What the large reviews show

The 884-trial review

A systematic review in the Journal of the American College of Cardiology, shared by Louis, pooled 884 randomized trials of 27 micronutrients in 883,627 participants. Its main findings were:

  • Omega-3 supplementation lowered cardiovascular mortality (RR 0.93), heart attack (RR 0.85) and coronary events (RR 0.86).
  • Folic acid lowered stroke risk (RR 0.84), and CoQ10 lowered all-cause mortality (RR 0.68; 95% CI 0.49-0.94).
  • Vitamin C, vitamin D, vitamin E and selenium showed no effect on cardiovascular disease or type 2 diabetes risk.
  • Beta-carotene increased all-cause mortality (RR 1.10), cardiovascular mortality (RR 1.12) and stroke (RR 1.09).
  • A long list (omega-3 and omega-6, L-arginine, L-citrulline, folic acid, vitamin D, magnesium, zinc, alpha-lipoic acid, CoQ10, melatonin, catechin, curcumin, flavanol, genistein and quercetin) showed moderate- to high-quality evidence for improving cardiovascular risk factors.3

The distinction matters: improving a risk factor is not the same as preventing events. Vitamin D, for instance, appears on the risk-factor list but showed no effect on cardiovascular disease risk itself.

Omega-3, folic acid and CoQ10 helped; beta-carotene harmedRelative risk with each supplement versus control, pooled review of 884 randomized trials (883,627 participants)
interval clear of 195% confidence interval
Omega-3: cardiovascular death0.93 (0.88–0.97)
Omega-3: heart attack0.85 (0.78–0.92)
Omega-3: coronary heart disease events0.86 (0.80–0.93)
Folic acid: stroke0.84 (0.72–0.97)
CoQ10: death from any cause0.68 (0.49–0.94)
Beta-carotene: death from any cause1.10 (1.05–1.15)
Beta-carotene: cardiovascular death1.12 (1.06–1.18)
Beta-carotene: stroke1.09 (1.01–1.17)
Vitamins C, D, E and selenium showed no effect on cardiovascular disease or type 2 diabetes. Each row pools different trials. Source: 3
Show data
Relative risk (log scale)95% CI
Omega-3: cardiovascular death0.930.88–0.97
Omega-3: heart attack0.850.78–0.92
Omega-3: coronary heart disease events0.860.80–0.93
Folic acid: stroke0.840.72–0.97
CoQ10: death from any cause0.680.49–0.94
Beta-carotene: death from any cause1.101.05–1.15
Beta-carotene: cardiovascular death1.121.06–1.18
Beta-carotene: stroke1.091.01–1.17

Guidance from Verdin's tiers

Louis also shared a five-tier framework from geroscientist Eric Verdin, ranking longevity supplements from Tier 1 (solid human data) to Tier 5 (the science says no). The content is in images only, so the placements are not recorded here.9

Supplements with the best support

Omega-3 fish oil (EPA and DHA)

A 2021 meta-analysis in Mayo Clinic Proceedings pooled 40 randomized trials with 135,267 participants. EPA/DHA supplementation was associated with a 13% lower risk of heart attack (RR 0.87; high-certainty evidence, number needed to treat 272), 10% lower coronary heart disease events, 35% lower fatal heart attack (moderate certainty) and 9% lower coronary mortality (low certainty), but not a lower rate of the broad cardiovascular-events composite. The effect looked dose dependent: each extra gram per day was linked to about 9% lower risk of coronary events and heart attack. The authors suggest 1,000-2,000 mg/day of EPA plus DHA.4

The post adds a warning: several RCTs showed a small increased risk of atrial fibrillation (an irregular heart rhythm) at high doses, so people at risk should talk to a cardiologist before taking high-dose fish oil.4

Omega-3 cut heart attacks, not all cardiovascular eventsRelative risk with EPA/DHA supplements versus control, meta-analysis of 40 randomized trials (135,267 participants, 2021)
interval clear of 1interval includes 1 (no clear difference)95% confidence interval
Heart attack0.87 (0.80–0.96)
Coronary heart disease events0.90 (0.84–0.97)
Fatal heart attack0.65 (0.46–0.91)
Coronary heart disease death0.91 (0.85–0.98)
Broad cardiovascular events composite0.95 (0.90–1.00)
Certainty was high for heart attack and coronary events, moderate for fatal heart attack and low for coronary death. Several trials showed a small rise in atrial fibrillation at high doses. Source: 4
Show data
Relative risk (log scale)95% CI
Heart attack0.870.80–0.96
Coronary heart disease events0.900.84–0.97
Fatal heart attack0.650.46–0.91
Coronary heart disease death0.910.85–0.98
Broad cardiovascular events composite0.950.90–1.00

Other points from the group:

  • Plaque. Louis lists high-dose EPA among six strategies with randomized evidence for plaque regression.10 In the EVAPORATE trial, icosapent ethyl 4 g/day cut vulnerable plaque by 17%; the plaque did not shrink much, but its type changed.11
  • Dose and testing. Rhonda Patrick, as summarized by Gokhan, describes the Omega-3 Index (EPA plus DHA in red blood cells) with under 4% as undesirable and over 8% as optimal, and says reaching 8% generally takes about 2 g/day.12 Peter Attia takes about 2 g EPA and 1.5 g DHA aiming for roughly 12% in red cells.13 These are personal regimens.
  • Not for everything. A review of 33 systematic studies found little evidence that omega-3 supplements build muscle or strength in healthy adults.14 A meta-analysis shared in the group found reduced aggressive behavior, which is unrelated to the heart.15
  • Quality and form. One review of nutraceuticals and small dense LDL found inconclusive results for 4 g/day of fish oil on LDL particle size.16

CoQ10 in heart failure

The Q-SYMBIO trial (JACC: Heart Failure, 2014) enrolled 420 patients with moderate to severe chronic heart failure at 17 centers in 9 countries. Half took 100 mg of ubiquinone three times daily for two years on top of standard care. The shared summary reports the primary composite endpoint in 15% versus 26% (a 43% relative reduction), cardiovascular mortality 9% versus 16%, and all-cause mortality 10% versus 18%.5 Louis calls CoQ10 the best-supported dietary intervention for cardiovascular death in heart failure, and the same summary stresses that CoQ10 was added to optimal therapy, not used instead of it.5 This is specific to heart failure, and the pooled review also found a lower all-cause mortality signal.3

Q-SYMBIO: CoQ10 added to heart failure care cut events and deathsShare of patients with each outcome over 2 years, 420 patients with moderate to severe chronic heart failure, 100 mg CoQ10 three times daily versus placebo
CoQ10Placebo
Primary composite (heart failure hospitalization, cardiovascular death, urgent transplant or mechanical support)15%26%
Cardiovascular death9%16%
Death from any cause10%18%
CoQ10 was added on top of standard heart failure therapy, not used instead of it. Source: 5
Show data
CoQ10Placebo
Primary composite (heart failure hospitalization, cardiovascular death, urgent transplant or mechanical support)15%26%
Cardiovascular death9%16%
Death from any cause10%18%

Folic acid and B vitamins

Beyond the pooled stroke result (RR 0.84), Louis cites a meta-analysis of 45 randomized trials in 96,962 people in which folic acid lowered stroke risk by 15%, and says RDA-level folic acid is associated with lower risk of stroke and colon cancer in the Harvard Nurses Study.317 A Tufts article he shared reports that certain groups, such as older people with high homocysteine at risk of dementia, benefit substantially from B vitamins.18

Louis argues against assuming methylfolate is superior. He says food folate is less bioavailable than folic acid, which is less bioavailable than methylfolate (5-MTHF), and that high folate levels may feed existing precancerous lesions, with worm and mouse data linking high methylfolate to shorter lifespan. These are his interpretations, and he suggests lower methylfolate doses or folate-rich foods instead.17 Attia nevertheless uses methylfolate and methyl B12 to keep homocysteine below 9.13 Here the group's sources differ.

Cocoa flavanols and multivitamins (the COSMOS trial)

COSMOS randomized more than 21,000 adults to 500 mg/day of cocoa flavanols, a multivitamin, both or neither for about 3.6 years. Total cardiovascular events fell 10%, which was not statistically significant. Cardiovascular death fell a significant 27%, and among people who took the pills regularly, total events fell 15% and cardiovascular death 39%. The authors urge cautious interpretation.1920 Louis calls it one of the highest-quality long-term supplement trials. A follow-up analysis reported that cocoa extract lowered hsCRP (an inflammation marker). Gokhan says he eats cocoa rather than supplementing.21 One member suggested a cheaper bulk cacao extract, estimating 1.5 g gives 500 mg flavanols; the supplier does not test flavanol content, so this is an unverified consumer tip.22

The multivitamin arm is best supported for cognition, not the heart:

  • A three-year analysis in adults over 65 estimated about 60% slower cognitive decline (about 1.8 years), with larger benefit in people with significant cardiovascular disease.23
  • A later pooled analysis put the benefit at about two years of slower cognitive aging, called modest; effects were unclear for attention and planning, dementia prevention was not tested, and the manufacturer donated tablets.24
  • An epigenetic-clock analysis in 958 participants (average age 70) found slowing equivalent to about four months of aging over two years, with editorialists saying "uncertainties remain."2526
  • The multivitamin contained B12 at about ten times the RDA, and Louis suspects B12 may drive the cognitive effect; a UCSF study of 231 older adults tied lower active B12 to slower processing speed and more white matter lesions.2728 He speculates the cognitive benefit may matter for people with heart disease, a hypothesis.29
  • In the Physicians' Health Study II (over 14,600 participants, 14 years) a multivitamin with 10x RDA of B12 showed an 8% lower cancer risk and no increase in any major disease.30

Mixed or early evidence

Vitamin D and magnesium

The pooled review found no effect of vitamin D on cardiovascular disease or type 2 diabetes.3 Advocates see it differently: Patrick says about 70% of people are at or below 30 ng/mL, suggests 4,000 IU/day with testing to reach 40-60 ng/mL, and cites magnesium needs of about 400 mg/day for men and 300-350 for women.12 Attia takes 5,000 IU daily but acknowledges the need for more rigorous vitamin D studies.13

Practical points from Louis: vitamin D2 may lower 25(OH)D by about 18 nmol/L, and D3 raises levels more, with 2,000-4,000 IU/day suggested for most adults.31 Supplements lack the sun's built-in feedback, so 20,000 IU/day for months risks hypercalcemia, which can cause cardiac arrest and arterial calcification.7 A UK coroner warned after an 89-year-old died of vitamin D toxicity.32

Vitamin K2

Evidence on K2 is the most debated topic in the group. A JAMA Cardiology randomized trial (2026) found two years of MK-7 reduced coronary calcium progression versus placebo in symptomatic coronary disease, mainly by limiting new calcification in noncalcified plaque. It did not change stenosis severity or total plaque volume, showed no relevant adverse effects, and its effect on events is unknown. Gokhan advises against K2 on warfarin without checking with a doctor.33

JAMA Cardiology's visual abstract of the K2 trial: 150 adults with symptomatic coronary disease and calcium scores of 50–400 took 360 µg of MK-7 or placebo daily for two years; MK-7 slowed the rise in calcium score by about 19 Agatston units a year.
JAMA Cardiology's visual abstract of the K2 trial: 150 adults with symptomatic coronary disease and calcium scores of 50–400 took 360 µg of MK-7 or placebo daily for two years; MK-7 slowed the rise in calcium score by about 19 Agatston units a year.33

Dr. Gil Carvalho, as summarized by Gokhan, is skeptical. Calcium is a marker of long-standing plaque, not the cause of risk, and no large powered trials show K2 reduces heart attacks or strokes; slowing calcification without reducing plaque could even be unhelpful, since calcium may stabilize plaque. The main danger is false reassurance.134 Louis takes K2 mainly for insulin sensitivity, citing three RCTs of MK-7 (90-360 mcg/day) that lowered fasting glucose and HbA1c in type 2 diabetes, though the source is a supplement-industry magazine.35

Taurine

A 2026 meta-analysis in Nutrition Reviews pooled 34 randomized trials in 1,394 people and found that oral taurine improved several cardiometabolic markers versus placebo or control; the post does not list which markers or the effect sizes.36 The broader taurine case, as Gokhan summarizes it, relies largely on animal and observational data.37 Gokhan has said he may have overdosed taurine and beta-alanine in the past.38

Berberine, curcumin and red yeast rice

  • Berberine lowered TMAO (a gut-derived compound linked to atherosclerosis) and plaque in a small human trial mentioned by Gokhan.39
  • 1,000 mg/day curcuminoids with 5 mg piperine reduced small dense LDL in one trial.16
  • Red yeast rice still lowers cholesterol through related monacolins even though US products are supposed to contain no lovastatin. Louis says it may suit people who cannot tolerate statins, but it is unregulated and variable, with no large trials showing fewer heart attacks, so it is a gamble for high-risk people.40

Supplements for plaque: promising but unproven

Louis notes that the supplements said to stop plaque rest on small, lower-quality studies that look promising but are uncertain; he considers gotu kola the most plausible mechanistically.1041 A Life Extension summary describes 60 mg of Centella asiatica extract three times daily hardening carotid plaque by 30% and femoral plaque by 63% over 12 months, with 41% fewer events in a randomized phase. Louis calls for larger trials.42

Aged garlic extract (about 1.2 g/day) slowed calcium progression in three small RCTs (for example 6.8% versus 26.5% in 65 patients), although two used co-supplements.43 Charles Grashow's calcium score fell from 102 to 32 while he took high-dose nattokinase, but also rosuvastatin, ezetimibe, telmisartan and other supplements, so it is a single case, not a trial.4445

For context, trials in the group show plaque regression with major weight loss, Mediterranean or DASH diets, LDL-lowering drugs, colchicine, exercise and high-dose EPA.1011

Possible harms and hype

  • L-arginine. In a Johns Hopkins trial of 153 heart attack survivors (3 g three times daily), the trial was stopped at six months with 6 deaths on arginine and none on placebo. Louis speculates citrulline may carry similar concern.6 Gokhan uses a lower 700 mg dose personally.38
  • L-carnitine. A 6-month trial in metabolic syndrome found worsening carotid plaque stenosis versus placebo, though plaque volume did not change; TMAO is the suspected mechanism.46
  • Glutathione. Louis argues oral glutathione barely enters cells and may disturb signaling outside them, favoring foods that raise production inside cells. This is mechanistic opinion.4748
  • NAD precursors. A Nature Metabolism study found whole-blood NAD stays stable with age, which makes commercial NAD blood tests of little use, and there is no convincing evidence NR or NMN slow human aging.49
  • Animal or tiny-sample findings. Alpha-ketoglutarate extended lifespan in worms and mice (Gokhan takes it).50 Vanadyl sulfate extended male mouse lifespan 7.4%, but vanadium is toxic.51 Tricaprin reversed lesions in just two patients with a rare condition.52 A ketone ester improved cardiac function only acutely.53
  • Turmeric and creatine. Louis argues that a turmeric liver-injury case report involved a normal dose and untested capsules.54 Creatine showed more cancer spread in animals, but human data are reassuring.55
  • Collagen and whey. Collagen improved skin and osteoarthritis symptoms but is a poor muscle protein.56 Louis says processed whey has no long-term data, unlike yogurt.57
  • Medicine interactions. Louis notes some supplements compound the anticoagulant effect of Eliquis, which is metabolized by CYP3A4.8

What this means for you

Where the main supplements stand in the group's posts34561719334243:

SupplementStrongest evidence sharedEffect on heart events
Omega-3 (EPA plus DHA)Meta-analyses of 40 and 884 randomized trialsFewer heart attacks (RR 0.85-0.87); possible atrial fibrillation risk at high doses
CoQ10Q-SYMBIO trial in heart failureCardiovascular death 9% vs 16% in heart failure
Folic acidMeta-analysis of 45 trialsAbout 15% fewer strokes
Cocoa flavanolsCOSMOS trial27% fewer cardiovascular deaths (secondary outcome); main endpoint not significant
Vitamins C, D, E, selenium884-trial reviewNo effect on cardiovascular disease
Vitamin K22026 JAMA Cardiology trialSlower calcium progression; effect on events unknown
Gotu kola, aged garlic, nattokinaseSmall studies or a single caseNot shown in large trials
Beta-carotene884-trial reviewHigher death rate (RR 1.10)
L-arginine after a heart attackTrial stopped early6 deaths vs 0 on placebo
  • Treat omega-3 (1,000-2,000 mg/day EPA plus DHA), CoQ10 in heart failure and folic acid for stroke as the best-supported options, and discuss them with your doctor.345
  • If you take fish oil at high doses, ask about atrial fibrillation risk.4
  • Avoid assuming a supplement proven to move a surrogate (calcium score, glucose, LDL) will prevent events.133
  • Be cautious with L-arginine after a heart attack and with carnitine.646
  • Test vitamin D levels before using high doses.712
  • Tell your doctor about all supplements, especially if you take blood thinners.833
  • Never use supplements instead of proven treatments.1 Gokhan and Hasselbalch published a review of heart drugs, supplements and lifestyle in polycythemia vera.58

Frequently asked questions

Does a multivitamin protect the heart?

The pooled review did not show benefit for vitamins C, D, E or selenium on cardiovascular disease.3 COSMOS supports modest cognitive and aging-marker benefits from a standard multivitamin, not proven heart protection.2425

Is fish oil worth taking?

Pooled trials suggest fewer heart attacks, with 1,000-2,000 mg/day suggested and some atrial fibrillation risk at high doses.4

Can supplements reverse plaque?

Not proven. Small studies and individual stories exist, but better-established routes are weight loss, diet, LDL-lowering drugs and exercise.1041

Is vitamin K2 worth it?

Debated: it slows calcium progression in a recent RCT but has no proven effect on events.3334

The evidence behind this summary52 studies · 5 meta-analyses · 23 trials · 4 observational

The 58 group posts cited above discuss 52 studies and sources. Their mix of study designs shows how much rests on randomized trials and meta-analyses, which can show cause and effect, and how much on observational, lab or animal work, which mostly cannot.

Meta-analyses 5Randomized trials 23Observational studies 4Reviews & guidelines 12Animal & lab studies 3Other sources 5

Strongest evidence discussed

All 52 studies and sources
Sources from the group (58)
  1. Dr Carvalho: evidence for vitamin K2 supplements and arterial calcium is weak Gokhan Can · Nov 16, 2025 · Facebook
  2. Absence of evidence is not evidence of absence: weighing unproven interventions Louis Nervegna · Oct 30, 2026 · Facebook
  3. Review of 884 supplement RCTs: omega-3, folic acid and CoQ10 helped; beta-carotene harmed Louis Nervegna · Nov 30, 2023 · Facebook
  4. Omega-3 supplementation across 40 RCTs lowered heart attack 13% and fatal heart attack 35% Louis Nervegna · Dec 20, 2025 · Facebook
  5. Q-SYMBIO: CoQ10 cut cardiovascular death in heart failure patients Louis Nervegna · Apr 18, 2026 · Facebook
  6. Johns Hopkins arginine RCT stopped early: 6 deaths vs 0 in heart-attack survivors Louis Nervegna · Nov 29, 2023 · Facebook
  7. Vitamin D from sun self-limits, but 20,000 IU/day supplements risk hypercalcemia Louis Nervegna · Aug 19, 2025 · Facebook
  8. Eliquis and supplements question; mother's suspected DVT proved a false positive Louis Nervegna · Dec 30, 2024 · Facebook
  9. Eric Verdin's five-tier evidence ranking for longevity supplements Louis Nervegna · Apr 09, 2026 · Facebook
  10. Six strategies shown to regress plaque in human randomized trials Louis Nervegna · Feb 27, 2025 · Facebook
  11. Evidence that plaque can shrink: CENIT, PRECISE-IVUS, ZEUS, EVAPORATE and GLAGOV Louis Nervegna · Jun 25, 2025 · Facebook
  12. Rhonda Patrick on micronutrient deficiencies and exercise for healthy aging Gokhan Can · Mar 08, 2024 · Facebook
  13. Peter Attia's current supplement stack Gokhan Can · Nov 23, 2023 · Facebook
  14. Review of 33 systematic studies finds little evidence omega-3 supplements build muscle Louis Nervegna · Mar 14, 2025 · Facebook
  15. Omega-3 supplements cut aggressive behavior by up to 28% in a 29-study meta-analysis Louis Nervegna · Jun 01, 2026 · Facebook
  16. Review: nuts, olive oil and nutraceuticals can lower small dense LDL Gokhan Can · Sep 04, 2024 · Facebook
  17. Methylfolate is not 'natural', and higher blood levels may promote cancer Louis Nervegna · Mar 11, 2026 · Facebook
  18. Tufts: B vitamins can help older people with high homocysteine protect brain and heart Louis Nervegna · Sep 08, 2025 · Facebook
  19. Cocoa flavanol extract cut CVD death 27% in the 21,000-person COSMOS trial Louis Nervegna · May 05, 2024 · Facebook
  20. COSMOS: cocoa flavanols cut cardiovascular death 27% in 21,000 adults over 3.6 years Louis Nervegna · Jul 19, 2024 · Facebook
  21. Cocoa extract supplement lowered hsCRP in older adults, reports COSMOS-based news Gokhan Can · Sep 26, 2025 · Facebook
  22. A cheaper high-polyphenol cocoa extract alternative to CocoaVia Louis Nervegna · Dec 10, 2025 · Facebook
  23. COSMOS: a daily multivitamin slowed cognitive decline by 60% over 3 years in older adults Louis Nervegna · Mar 29, 2025 · Facebook
  24. Daily multivitamin slowed cognitive aging by about two years in a COSMOS meta-analysis Louis Nervegna · Nov 14, 2026 · Facebook
  25. COSMOS: 2 years of a basic multivitamin slowed biological aging by about 4 months Louis Nervegna · Mar 09, 2026 · Facebook
  26. COSMOS trial: daily multivitamin may slow biological aging markers, with editorial caveats Louis Nervegna · Mar 09, 2026 · Facebook
  27. COSMOS multivitamin matches Centrum-type RDA doses except B12 at 10x the RDA Louis Nervegna · Nov 15, 2026 · Facebook
  28. Even 'normal' vitamin B12 may be too low for older brains; active B12 tied to lesions Louis Nervegna · May 23, 2026 · Facebook
  29. Multivitamin trials slow cognitive decline; possible relevance to heart disease patients Louis Nervegna · Jan 19, 2024 · Facebook
  30. High vitamin B12 in a multivitamin did not raise disease risk in a 14-year Harvard trial Louis Nervegna · Oct 02, 2026 · Facebook
  31. Vitamin D2 supplements may lower 25(OH)D by about 18 nmol/L; choose D3 Louis Nervegna · Oct 17, 2025 · Facebook
  32. Vitamin D overdose caused fatal hypercalcemia in an 89-year-old, UK coroner warns Louis Nervegna · Jan 21, 2026 · Facebook
  33. JAMA Cardiology trial: vitamin K2 (MK-7) for 2 years slowed coronary calcium progression Gokhan Can · Jun 10, 2026 · Facebook
  34. New vitamin K2 trial slowed arterial calcification but did not reduce plaque, video argues Gokhan Can · Aug 31, 2026 · Facebook
  35. Vitamin K2 trials show better glucose and HbA1c in type 2 diabetes, per Life Extension Louis Nervegna · Sep 09, 2024 · Facebook
  36. Meta-analysis of 34 RCTs: taurine supplements improved several cardiometabolic markers Louis Nervegna · Feb 26, 2026 · Facebook
  37. Taurine and cardiovascular disease: anti-inflammatory and vascular effects Gokhan Can · Jan 27, 2024 · Facebook
  38. A personal 'cocktail of metabolites' for longevity: AKG, arginine, beta-alanine, taurine Gokhan Can · May 12, 2024 · Facebook
  39. Strategies for lowering TMAO: diet, supplements and repurposed drugs Gokhan Can · Aug 29, 2025 · Facebook
  40. Red yeast rice vs statins: lovastatin removed, other monacolins remain, no outcome RCTs Louis Nervegna · Feb 11, 2024 · Facebook
  41. Plaque-stopping supplements rest on small, low-quality studies; gotu kola most plausible Louis Nervegna · Dec 17, 2024 · Facebook
  42. Gotu kola extract reportedly stabilized high-risk plaque in small studies Louis Nervegna · Nov 17, 2023 · Facebook
  43. Aged garlic extract slowed coronary calcium progression in three small RCTs Gokhan Can · Nov 17, 2023 · Facebook
  44. Charles Grashow's protocol to regress coronary calcium over two years Gokhan Can · Dec 02, 2023 · Facebook
  45. The longer the lower the better: lifelong LDL lowering and an estimated 60% risk reduction Gokhan Can · Nov 20, 2023 · Facebook
  46. L-carnitine supplements increased carotid plaque stenosis in a 6-month RCT Louis Nervegna · Jul 18, 2025 · Facebook
  47. Glutathione supplements mostly end up outside cells, where they don't belong Louis Nervegna · Jul 30, 2026 · Facebook
  48. Glutathione supplements are probably a bad idea long term Louis Nervegna · Jul 04, 2026 · Facebook
  49. Blood NAD levels do not fall with age, so commercial NAD blood tests are useless Louis Nervegna · Oct 24, 2026 · Facebook
  50. Alpha-ketoglutarate (AKG): longevity data in worms and mice, plus anti-thrombotic effects Gokhan Can · Mar 02, 2024 · Facebook
  51. Vanadyl sulfate cleared senescent cells and extended male mouse lifespan 7.4% Louis Nervegna · Nov 12, 2026 · Facebook
  52. Tricaprin supplement reversed atherosclerosis in two patients with TGCV Gokhan Can · Jan 09, 2025 · Facebook
  53. Ketone ester drink acutely improved cardiac function in a small type 2 diabetes study Gokhan Can · Feb 12, 2025 · Facebook
  54. Turmeric liver case report criticised: 2.25 g is a normal intake, no contamination test Louis Nervegna · Jul 11, 2025 · Facebook
  55. Creatine and cancer metastasis: preclinical signal, but human evidence is reassuring Louis Nervegna · Sep 18, 2026 · Facebook
  56. Largest collagen review (113 trials): helps skin and osteoarthritis, little for muscle Louis Nervegna · Jun 06, 2026 · Facebook
  57. Yogurt has long-term evidence behind it; processed whey supplements do not Louis Nervegna · Jul 09, 2026 · Facebook
  58. Mergen and Hasselbalch review heart drugs, supplements and lifestyle in polycythemia vera Gokhan Can · Jun 11, 2026 · Facebook

Keep exploring

Related research summaries

Topics and hashtags in this summary